Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Steg

Showing results (751-760 of 962) with videos related to

Pageof 97
Sort By:
NEJM Evidence|February 6, 2024
Bentracimab for Ticagrelor Reversal in Patients Undergoing Urgent SurgeryDeepak L Bhatt, Charles V Pollack, C David Mazer, et al.
American Heart Journal|June 17, 2004
Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) multinational studyAlan S Maisel, Paul Clopton, Padma Krishnaswamy, et al.
JAMA Network Open|February 14, 2022
Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin TreatmentWilliam S Weintraub, Deepak L Bhatt, Zugui Zhang, et al.
Journal of the American College of Cardiology|July 11, 2020
Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCIGuillaume Marquis-Gravel, Frederik Dalgaard, Aaron D Jones, et al.
Journal of the American Heart Association|June 23, 2016
Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart DiseaseLars Wallentin, Claes Held, Paul W Armstrong, et al.
Lancet (London, England)|September 6, 2019
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trialDeepak L Bhatt, Philippe Gabriel Steg, Shamir R Mehta, et al.
European Journal of Preventive Cardiology|March 23, 2021
Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trialRafael Diaz, Qian H Li, Deepak L Bhatt, et al.
Journal of the American Heart Association|August 23, 2021
Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 TrialBrian A Bergmark, Deepak L Bhatt, P Gabriel Steg, et al.
Circulation|November 12, 2019
Effect of Alirocumab on Stroke in ODYSSEY OUTCOMESJ Wouter Jukema, Laurien E Zijlstra, Deepak L Bhatt, et al.
The New England Journal of Medicine|November 17, 2020
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart FailureDeepak L Bhatt, Michael Szarek, P Gabriel Steg, et al.
Pageof 97

Showing results (751-760 of 962) with videos related to

Sort By:
Pageof 97
NEJM Evidence|February 6, 2024
Bentracimab for Ticagrelor Reversal in Patients Undergoing Urgent SurgeryDeepak L Bhatt, Charles V Pollack, C David Mazer, et al.
American Heart Journal|June 17, 2004
Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) multinational studyAlan S Maisel, Paul Clopton, Padma Krishnaswamy, et al.
JAMA Network Open|February 14, 2022
Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin TreatmentWilliam S Weintraub, Deepak L Bhatt, Zugui Zhang, et al.
Journal of the American College of Cardiology|July 11, 2020
Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCIGuillaume Marquis-Gravel, Frederik Dalgaard, Aaron D Jones, et al.
Journal of the American Heart Association|June 23, 2016
Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart DiseaseLars Wallentin, Claes Held, Paul W Armstrong, et al.
Lancet (London, England)|September 6, 2019
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trialDeepak L Bhatt, Philippe Gabriel Steg, Shamir R Mehta, et al.
European Journal of Preventive Cardiology|March 23, 2021
Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trialRafael Diaz, Qian H Li, Deepak L Bhatt, et al.
Journal of the American Heart Association|August 23, 2021
Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 TrialBrian A Bergmark, Deepak L Bhatt, P Gabriel Steg, et al.
Circulation|November 12, 2019
Effect of Alirocumab on Stroke in ODYSSEY OUTCOMESJ Wouter Jukema, Laurien E Zijlstra, Deepak L Bhatt, et al.
The New England Journal of Medicine|November 17, 2020
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart FailureDeepak L Bhatt, Michael Szarek, P Gabriel Steg, et al.
Pageof 97